Filter run time in CVVH: Pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation

Blood Purification

Volumn 23, Issue 3, 2005, Pages 175-180

  Van Der Voort, P H J ^a   Gerritsen, R T ^a   Kuiper, M A ^a   Egbers, P H M ^a   Kingma, W P ^a   Boerma, E C ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Coagulation; Continuous veno venous haemofiltration; Heparin; Intensive care; Nadroparin; Post dilution; Pre dilution

Indexed keywords

HEPARIN; NADROPARIN; PROTAMINE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DILUTION; FEMALE; HEMOFILTRATION; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STANDARDIZATION;

AGED; ANTICOAGULANTS; HEMOFILTRATION; HEPARIN ANTAGONISTS; HUMANS; MALE; NADROPARIN; PROTAMINES;

EID: 21044454215     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083938     Document Type: Article

References (14)

1. Bellomo R, Ronco C: Continuous renal replacement therapy in the intensive care unit. Intensive Care Med 1999;25:781-789.
2. Santoro A, Mancini E, Zucchelli P: The impact of haemofiltration on the systemic cardiovascular response. Nephrol Dial Transplant 2000;15(suppl 2):49-54.
3. Van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC: Heparin use in continuous renal replacement procedures: The struggle between filter clotting and patient hemorrhage. J Am Soc Nephrol 1996;7:145-150.
4. Davenport A, Mehta S: The acute dialysis quality initiative. VI. Access and anticoagulation in CRRT. Adv Ren Replace Ther 2002;9:273-281.
5. Van Bommel EFH: Renal replacement therapy for acute renal failure on the intensive care unit: Coming of age? Neth J Med 2003;61:239-248.
6. Nice Data Dictionary: www.stichting-nice.nl (last visited April 2, 2004).
7. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829.
8. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: Impact on filter life and azotemic control. Nephron Clin Pract 2003;94:94-98.
9. Ovrum E, Lindberg H, Holen EA, Abdelnoor M, Bech J: Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man. Scand J Thorac Cardiovasc Surg 1991;25:19-24.
10. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD: A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999;27:2224-2228.
11. De Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF: Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous haemofiltration: A double-blind, randomized, crossover study. Crit Care Med 2000;28:421-425.
12. Vargas Hein O, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C: Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 2001;27:673-679.
13. Abramson S, Niles JL: Anticoagulation in continuous renal replacement therapy. Curr Opin Nephrol Hypertens 1999;8:701-707.
14. Hidalgo N, Hynes-Gay P, Hill S, Burry L: Anticoagulation in continuous renal replacement therapy. Dynamics 2001;12:13-17.